Mark W. Surber

Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis

Gali Epstein Shochet, Becky Bardenstein-Wald, Mary McElroy et al. · International Journal of Molecular Sciences · 2021 · 47 citations · Full text

Inhaled nintedanib is well-tolerated and delivers key pharmacokinetic parameters required to treat bleomycin-induced pulmonary fibrosis

Mark W. Surber, Steve Beck, Stephen Pham et al. · Pulmonary Pharmacology & Therapeutics · 2020 · 39 citations · Full text

Antifibrotic Therapy, Inflammatory Lung Disease, Bleomycin-induced Pulmonary Fibrosis +12

A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis

Jun Keng Khoo, A. Bruce Montgomery, Kelly Otto et al. · Journal of Aerosol Medicine and Pulmonary Drug Delivery · 2019 · 37 citations · Full text

Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: a Viable Approach to Treating Idiopathic Pulmonary Fibrosis

Lisa M. Kaminskas, Cornelia B. Landersdorfer, Robert J. Bischof et al. · Pharmaceutical Research · 2019 · 31 citations · Full text

Lung Deposition, Inflammatory Lung Disease, Medicine +8

Single-dose pharmacokinetics of aerosol MP-376 (levofloxacin solution for inhalation) in cystic fibrosis patients: PK-PD implications

P.C. Griffith, Carrinna Hansen, T. Pressler et al. · Journal of Cystic Fibrosis · 2008 · 28 citations · Full text

Pharmaceutical Science, Cystic Fibrosis Patients, Pharmacology +7